Frankincense / Boswellia

Metadata

Approved Indications

German Commission E

• No monograph exists — Boswellia is not a traditional European medicinal plant and was not assessed by the original Commission E

ESCOP

• No monograph exists to date [NEEDS-RESEARCH — confirm current ESCOP status]

EMA/HMPC

• No full herbal monograph for therapeutic use
• Boswellia serrata IS listed in the EMA’s Inventory of Herbal Substances for assessment, but a full monograph has not been completed
• European Pharmacopoeia 6.0: Contains a quality monograph for “Indian Frankincense” (Olibanum indicum) standardizing to 11-keto-beta-boswellic acid (KBA) and acetyl-11-keto-beta-boswellic acid (AKBA) content
• Orphan drug designation: EMA granted orphan drug status for Boswellia serrata resin extract for treatment of peritumoral brain edema (2002)

WHO and Other Bodies

• WHO Monograph exists for Boswellia
• Indian Pharmacopoeia includes Boswellia

Agreement/Disagreement Among Authorities

• Significant gap: Unlike the other herbs in this module, Boswellia lacks Commission E, ESCOP, and full EMA therapeutic monographs. This is NOT because of weak evidence but because it originates from the Ayurvedic tradition rather than European herbalism
• European Pharmacopoeia recognition of quality standards signals growing European acceptance
• Clinical evidence exceeds regulatory recognition — the RCT base is arguably stronger than that of some herbs that DO have full monographs

Conditions Treated

Primary (Evidence-Supported)

• Knee osteoarthritis — strongest evidence base (multiple RCTs)
• Hip osteoarthritis — extrapolated from knee OA data
• Rheumatoid arthritis — moderate evidence from older studies

Secondary (Supported by Smaller Studies/Traditional Use)

• Inflammatory bowel disease (ulcerative colitis, Crohn’s disease)
• Asthma (traditional Ayurvedic indication; some clinical trials)
• Peritumoral brain edema (EMA orphan drug designation)
• Tendinitis and other soft tissue inflammation [NEEDS-RESEARCH]

Mechanism of Action

Key Active Compounds

• Boswellic acids (pentacyclic triterpenes) — the primary therapeutic class:
  • AKBA (3-O-acetyl-11-keto-beta-boswellic acid) — most potent 5-LOX inhibitor
  • KBA (11-keto-beta-boswellic acid)
  • Beta-boswellic acid (BBA)
  • Acetyl-beta-boswellic acid (ABBA)
• Total boswellic acid content in crude resin: ~30% by weight
• AKBA content in crude resin: ~2-3% (enriched to 30% in 5-Loxin)

Pharmacological Mechanisms

1. 5-Lipoxygenase (5-LOX) inhibition: AKBA is a potent, selective inhibitor of 5-LOX, the enzyme responsible for leukotriene synthesis. This is a UNIQUE mechanism not shared by NSAIDs (which target COX). Leukotrienes (LTB4, LTC4, LTD4) are powerful pro-inflammatory mediators in chronic inflammation [Source: Ammon, 2006]
2. NF-kB suppression: Boswellic acids inhibit NF-kB activation, reducing transcription of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6)
3. COX-2 modulation: Some evidence for COX-2 inhibition, though this is secondary to the 5-LOX pathway
4. MMP inhibition: May protect cartilage by inhibiting matrix metalloproteinases involved in cartilage degradation
5. Complement inhibition: Reduces complement-mediated inflammation
6. Cathepsin G and elastase inhibition: Additional anti-inflammatory mechanisms targeting serine proteases

Unique Therapeutic Positioning

The 5-LOX inhibition mechanism is clinically significant because:

• NSAIDs do NOT inhibit 5-LOX (they may even shunt arachidonic acid toward the 5-LOX pathway)
• This makes Boswellia genuinely complementary to, rather than duplicative of, NSAID therapy
• The dual 5-LOX/NF-kB mechanism addresses both leukotriene-mediated and cytokine-mediated inflammation

Clinical Evidence Summary

Systematic Reviews and Meta-Analyses

• Yu et al. (2020): Systematic review and meta-analysis of 7 RCTs (n=545) for osteoarthritis. Concluded that Boswellia and its extracts may relieve pain and stiffness; recommended minimum 4-week treatment duration [Source: BMC Complement Med Ther 2020]
• Multiple narrative reviews confirm moderate-quality evidence supporting efficacy in OA

Key Individual Trials

Knee Osteoarthritis (Proprietary Extracts)

Older/Traditional-Dose Studies

Effect Sizes

• Pain reduction: Typically 40-65% reduction in VAS pain scores over 90 days (vs. ~15-25% for placebo)
• Onset of effect: As early as 5-7 days with enriched AKBA extracts
• Functional improvement: Significant improvements in Lequesne index and WOMAC subscales

Limitations

• Many studies are funded by extract manufacturers (5-Loxin, Aflapin)
• Sample sizes generally modest (30-75 patients)
• Most studies conducted in India, not Europe
• Head-to-head comparisons with NSAIDs are limited [NEEDS-RESEARCH]
• Long-term studies (>6 months) are sparse

European vs. US/Anglophone Consensus

Unusual situation: Boswellia is BETTER known in the US supplement market than in European phytotherapy practice, which is the opposite pattern from Devil’s Claw and Willow Bark. However, the European regulatory framework has not yet fully integrated it, despite European Pharmacopoeia quality standards existing.

Safety Profile

Contraindications

• Pregnancy: Contraindicated. May stimulate uterine contractions and increase menstrual flow; traditional use as emmenagogue. Risk of miscarriage
• Lactation: Insufficient data; avoid use
• Known allergy to Burseraceae family

Drug Interactions

• No known severe or serious interactions
• NSAIDs: Theoretical additive anti-inflammatory effects (may be used intentionally in combination)
• Anticoagulants (warfarin): May increase bleeding risk (theoretical; monitor INR)
• CYP450 substrates: Some evidence of moderate interaction with hepatically metabolized drugs (CYP3A4, CYP2C9) [NEEDS-RESEARCH — magnitude of clinical significance unclear]
• Immunosuppressants: Theoretical interaction due to immune-modulating effects

Side Effects

• Generally well-tolerated
• GI effects: Mild nausea, diarrhea, epigastric discomfort, heartburn (uncommon; ~3-5%)
• Skin rash (rare)
• Acid reflux (occasional)
• No hepatotoxicity, nephrotoxicity, or significant hematological effects reported in clinical trials

Pregnancy and Lactation

• Pregnancy: CONTRAINDICATED. May induce miscarriage and increase menstrual flow
• Lactation: Insufficient data; avoid use as precaution

Clinical Dosage

Recommended Forms and Doses

Key Dosing Principles

1. AKBA content matters: Higher AKBA extracts (5-Loxin, Aflapin) show faster onset and require lower total doses
2. Minimum duration: 4 weeks minimum; optimal results at 8-12 weeks
3. Take with food: Fat-containing meals improve absorption of lipophilic boswellic acids
4. Bioavailability challenge: Boswellic acids have poor oral bioavailability; formulation technology (e.g., Aflapin’s non-acidic gum component) attempts to address this
5. Onset of effect: 5-7 days with enriched extracts; 2-4 weeks with standard extracts

Key Products

• 5-Loxin (PLT Health Solutions) — 30% AKBA enriched extract
• Aflapin (Laila Nutraceuticals) — AKBA + non-acidic gum synergistic composition
• Shallaki (Himalaya) — traditional Ayurvedic preparation
• Various European and US supplement brands offer standardized extracts (typically 60-65% boswellic acids)

Sources

• Yu G et al. Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. BMC Complement Med Ther. 2020;20(1):225.
• Sengupta K et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther. 2008;10(4):R85.
• Sengupta K et al. Comparative efficacy and tolerability of 5-Loxin and Aflapin against osteoarthritis of the knee. Int J Med Sci. 2010;7(6):366-377.
• Sengupta K et al. A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin in subjects with osteoarthritis of knee. Int J Med Sci. 2011;8(7):615-622.
• Ammon HP. Boswellic acids in chronic inflammatory diseases. Planta Med. 2006;72(12):1100-1116.
• European Pharmacopoeia 6.0. Indian Frankincense (Olibanum indicum) monograph.
• EMA. Orphan designation for Boswellia serrata resin extract. EU/3/02/117.
• Kimmatkar N et al. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee. Phytomedicine. 2003;10(1):3-7.
• Frontiers in Pharmacology 2024. Standardized Boswellia serrata extract shows improvements in knee OA within 5 days.

Connections

• Compare with Devils Claw — both oral anti-inflammatories for OA; Devil’s Claw has better European regulatory integration
• Compare with Stinging Nettle Leaf — both used as adjuvants in arthritis